Evidence-based Comparison of the Synovasure® Alpha Defensin ELISA Test and Alpha Defensin Lateral Flow Test
Overview:

Alpha defensin biomarker testing is the first test specifically designed and validated for use, as an adjunct to additional tests, in the diagnosis of periprosthetic joint infection (PJI). The test detects human alpha defensins in the synovial fluid of persons with a total joint replacement. Alpha defensins are antimicrobial peptides released by activated neutrophils in response to infection. There are two test options available: an ELISA test (available via laboratory) and a lateral flow device.

**Synovasure Alpha Defensin ELISA Test**

Synovasure Alpha Defensin ELISA test is a validated laboratory service performed by trained personnel in a certified laboratory (ie. CLIA (US), DAkkS (Germany), UKAS (UK)) with, typically, a 24–48 hours result turnaround. The Synovasure Alpha Defensin ELISA test is available in the US via CD Laboratories and in the EU via partner labs, the Fenner lab (Germany) and Golden Jubilee National Laboratory (UK).

**Synovasure Alpha Defensin Lateral Flow Test**

Synovasure Alpha Defensin Lateral Flow Test utilizes the same anti-microbial peptide to detect the immune response to infection as the ELISA test, but returns results in 10 minutes. The Synovasure Alpha Defensin Lateral Flow Test is available for use in numerous countries throughout the world.

**Clinical Validation**

In numerous clinical studies, both Synovasure Alpha Defensin test options demonstrated high levels of clinical performance through high sensitivity and specificity (see data table below).

### Synovasure Alpha Defensin ELISA Test

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rothman Institute¹</td>
<td>149</td>
<td>97% (36/37)</td>
<td>96% (107/112)</td>
</tr>
<tr>
<td>Mayo Clinic²</td>
<td>61</td>
<td>100% (19/19)</td>
<td>95% (40/42)</td>
</tr>
<tr>
<td>Cleveland Clinic³</td>
<td>78</td>
<td>100% (24/24)</td>
<td>98% (53/54)</td>
</tr>
<tr>
<td>Endo Klinik⁴</td>
<td>156</td>
<td>97% (28/29)</td>
<td>97% (123/127)</td>
</tr>
<tr>
<td>Cleveland Florida⁵</td>
<td>70</td>
<td>97% (34/35)</td>
<td>97% (34/35)</td>
</tr>
<tr>
<td>Charite – Universitätsmedizin Berlin⁶</td>
<td>71</td>
<td>85% (11/13)*</td>
<td>98% (57/58)</td>
</tr>
<tr>
<td>Multi-center Study⁷**</td>
<td>369</td>
<td>93% (113/122)</td>
<td>98% (241/247)</td>
</tr>
<tr>
<td><strong>Combined</strong></td>
<td>954</td>
<td>95% (265/279)</td>
<td>97% (655/675)</td>
</tr>
</tbody>
</table>

**Synovasure Alpha Defensin Lateral Flow**

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multi-center Study⁷**</td>
<td>288</td>
<td>94.3% (50/53)</td>
<td>94.5% (222/235)</td>
</tr>
</tbody>
</table>

Note: Excludes samples with >20% blood

* Includes patients with a draining sinus
** Mayo Clinic, Cleveland Clinic – Florida, Sinai Hospital of Baltimore
Lateral Flow Studies: Understanding the Differences

Several studies have been published that assess the performance of the Synovasure Alpha Defensin Lateral Flow device. A number of factors can influence the performance and results of these studies; e.g.

- Using small sample sizes especially with low numbers of PJI positives can misrepresent performance of the test
- Potential misuse of LF device such as improper dilution of samples - user should always follow the manufacturer’s instructions for use
- Use of criteria different from MSIS as the reference method
- Inclusion of joints with spacers

ELISA Test vs. Lateral Flow Test

In a multi-center prospective clinical study, no statistically significant difference was shown between Synovasure Alpha Defensin ELISA Test and Synovasure Alpha Defensin Lateral Flow Test. Furthermore, two recently published clinical studies performed a comparison between the tests:

- Gehrke, et al., demonstrated a 94.8% accuracy between the ELISA and Lateral Flow Test.
- Balato, et al., concluded that “The diagnostic accuracy of the two alpha-defensin assessment methods is comparable.”

The Synovasure Alpha Defensin ELISA Test and the Synovasure Alpha Defensin Lateral Flow Test perform nearly equivalent with no statistically significant difference. The tests achieve a sensitivity and specificity of 94% or greater, which can be seen from the clinical studies for both.
References


All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet.

This material is intended for health care professionals. Distribution to any other recipient is prohibited. For indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see the package insert or contact your local representative; visit www.zimmerbiomet.com for additional product information.

Not for distribution in France.

Check for country product clearances and reference product specific instructions for use.

© 2019 Zimmer Biomet